{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T13:36:16Z","timestamp":1782653776835,"version":"3.54.5"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The newly emerged Omicron subvariants demonstrate resistance to current therapeutic antibodies and an enhanced ability to evade the vaccine-induced immune responses. Among them, JN.1 sublineages are considered highly immune-evasive, underscoring the urgent need for broadly protective vaccines. Ferritin nanoparticles, with their unique hollow nanocage structure, provide an efficient antigen-display platform for next-generation vaccine development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Based on the previously constructed Delta-6P-S recombinant protein vaccine with broad-spectrum protective effects, this study optimized the S protein structure displayed on the surface of ferritin nanoparticles by comparing the immune responses induced in C57BL\/6J mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Delta-4S1158 nanoparticles, containing a truncated S-6P structure with four additional mutation sites, elicited robust S-specific immunoglobulin G (IgG), potent neutralizing antibodies, and a Th2-biased T-cell response in C57BL\/6J mice, demonstrating favorable immunogenicity and safety. The JN.1-4S1158 nanoparticles, based on this structural design, induced a strong cross-neutralizing antibody response in C57BL\/6J mice and conferred effective protection against Omicron BA.5, XBB, and JN.1 variants. Vaccinated mice exhibited significantly reduced viral genomic loads in trachea and lung tissues compared to controls, with no infectious virus detected. Lung tissue pathology was minimal in vaccinated mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The JN.1-4S1158 nanoparticle vaccine demonstrates broad-spectrum protective effects against Omicron subvariants and shows potential for further development. It also provides a basis for the development of a universal SARS-CoV-2 vaccine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2025.1676592","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T07:12:55Z","timestamp":1762240375000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Ferritin nanoparticle vaccine displaying optimized spike protein confers broad protection against Omicron subvariants"],"prefix":"10.3389","volume":"15","author":[{"given":"Sheng","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Tong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo-Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12101112","article-title":"Ferritin vaccine platform for animal and zoonotic viruses","volume":"12","author":"Ahmadivand","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s43556-025-00258-7","article-title":"A promising mRNA vaccine derived from the JN.1 spike protein confers protective immunity against multiple emerged Omicron variants","volume":"6","author":"Ao","year":"2025","journal-title":"Mol. Biomed."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4726","DOI":"10.1038\/s41467-025-59826-8","article-title":"Mpox multiprotein virus-like nanoparticle vaccine induces neutralizing and protective antibodies in mice and non-human primates","volume":"16","author":"Belghith","year":"2025","journal-title":"Nat. Commun."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29174221","article-title":"Self-assembled ferritin nanoparticles for delivery of antigens and development of vaccines: from structure and property to applications","volume":"29","author":"Cao","year":"2024","journal-title":"Molecules"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70206","article-title":"Continuous tracking for effective tackling: Ad5\/35 platform-based JN1 lineage vaccines development in response to evolving SARS-CoV-2 variants","volume":"97","author":"Chang","year":"2025","journal-title":"J. Med. Virol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41579-025-01185-8","article-title":"SARS-CoV-2 spike protein: structure, viral entry and variants","volume":"23","author":"Chen","year":"2025","journal-title":"Nat. Rev. Microbiol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.138405","article-title":"Self-assembling nanoparticle vaccine elicits a robust protective immune response against avian influenza H5N6 virus in chickens","volume":"287","author":"Chen","year":"2025","journal-title":"Int. J. Biol. Macromol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.virs.2024.09.005","article-title":"Ferritin nanoparticle-based Nipah virus glycoprotein vaccines elicit potent protective immune responses in mice and hamsters","volume":"39","author":"Chen","year":"2024","journal-title":"Virol. Sin."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10689","article-title":"Single immunization with an influenza hemagglutinin nanoparticle-based vaccine elicits durable protective immunity","volume":"9","author":"Chiba","year":"2024","journal-title":"Bioeng. Transl. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1080\/14760584.2025.2505754","article-title":"Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis","volume":"24","author":"Fahrbach","year":"2025","journal-title":"Expert Rev. Vaccines"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29160","article-title":"Subunit vaccine raised against the SARS-CoV-2 spike of Delta and Omicron variants","volume":"95","author":"Feng","year":"2023","journal-title":"J. Med. Virol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12879-025-10685-0","article-title":"JN.1 variants circulating in Italy from October 2023 to April 2024: genetic diversity and immune recognition","volume":"25","author":"Giombini","year":"2025","journal-title":"BMC Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-04441-6","article-title":"SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters","volume":"603","author":"Halfmann","year":"2022","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev-virology-093022-013037","article-title":"The emergence and evolution of SARS-CoV-2","volume":"11","author":"Holmes","year":"2024","journal-title":"Annu. Rev. Virol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110143","article-title":"SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity","volume":"37","author":"Joyce","year":"2021","journal-title":"Cell Rep."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abi5735","article-title":"A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates","volume":"14","author":"Joyce","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(23)00813-7","article-title":"Virological characteristics of the SARS-CoV-2 JN.1 variant","volume":"24","author":"Kaku","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1080\/21645515.2020.1796425","article-title":"Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19","volume":"16","author":"Karthik","year":"2020","journal-title":"Hum. Vaccin Immunother."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00464-25","article-title":"Neutralization and spike stability of JN.1-derived LB.1, KP.2.3, KP.3, and KP.3.1.1 subvariants","volume":"16","author":"Li","year":"2025","journal-title":"mBio"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1007\/s00705-022-05562-z","article-title":"Immunogenicity and protective efficacy of a DNA vaccine inducing optimal expression of the SARS-CoV-2 S gene in hACE2 mice","volume":"167","author":"Li","year":"2022","journal-title":"Arch. Virol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1080\/22221751.2021.2002670","article-title":"Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models","volume":"10","author":"Li","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.str.2024.06.012","article-title":"Spike structures, receptor binding, and immune escape of recently circulating SARS-CoV-2 Omicron BA.2.86, JN.1, EG.5, EG.5.1, and HV.1 sub-variants","volume":"32","author":"Li","year":"2024","journal-title":"Structure"},{"key":"B24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jconrel.2024.12.003","article-title":"Enhancing protective immunity against SARS-CoV-2 with a self-amplifying RNA lipid nanoparticle vaccine","volume":"378","author":"Lin","year":"2025","journal-title":"J. Control Release"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29174045","article-title":"Bioactive molecules delivery through ferritin nanoparticles: sum up of current loading methods","volume":"29","author":"Lucignano","year":"2024","journal-title":"Molecules"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens14010023","article-title":"An update on anti-COVID-19 vaccines and the challenges to protect against new SARS-CoV-2 variants","volume":"14","author":"Mambelli","year":"2025","journal-title":"Pathogens"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.126966","article-title":"Durability of COVID-19 vaccine and infection induced immunity: A systematic review and meta-regression analysis","volume":"54","author":"Moore","year":"2025","journal-title":"Vaccine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"20499361251314763","DOI":"10.1177\/20499361251314763","article-title":"The JN.1 variant of COVID-19: immune evasion, transmissibility, and implications for global health","volume":"12","author":"Naveed Siddiqui","year":"2025","journal-title":"Ther. Adv. Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29915","article-title":"A humanized ACE2 mouse model recapitulating age- and sex-dependent immunopathogenesis of COVID-19","volume":"96","author":"Park","year":"2024","journal-title":"J. Med. Virol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"126053","DOI":"10.1016\/j.vaccine.2024.06.021","article-title":"Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis","volume":"42","author":"Pischel","year":"2024","journal-title":"Vaccine"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13040424","article-title":"Beyond the pandemic era: recent advances and efficacy of SARS-CoV-2 vaccines against emerging variants of concern","volume":"13","author":"Saha","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41467-023-44265-0","article-title":"Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques","volume":"15","author":"Sankhala","year":"2024","journal-title":"Nat. Commun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1021\/acsnano.4c12212","article-title":"Nanoparticle vaccine triggers interferon-gamma production and confers protective immunity against porcine reproductive and respiratory syndrome virus","volume":"19","author":"Sun","year":"2025","journal-title":"ACS Nano"},{"key":"B34","doi-asserted-by":"publisher","first-page":"712","DOI":"10.4049\/immunohorizons.2400030","article-title":"Human ACE2 gene replacement mice support SARS-CoV-2 viral replication and nonlethal disease progression","volume":"8","author":"Thiede","year":"2024","journal-title":"ImmunoHorizons"},{"key":"B35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41590-024-02051-0","article-title":"T cell immune evasion by SARS-CoV-2 JN.1 escapees targeting two cytotoxic T cell epitope hotspots","volume":"26","author":"Tian","year":"2025","journal-title":"Nat. Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-023-06750-w","article-title":"Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike","volume":"624","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chom.2024.01.014","article-title":"XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1","volume":"32","author":"Wang","year":"2024","journal-title":"Cell Host Microbe"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1039\/d3tb00192j","article-title":"Ferritin nanocages: a versatile platform for nanozyme design","volume":"11","author":"Wang","year":"2023","journal-title":"J. Mater. Chem. B"},{"key":"B39","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10787-024-01627-4","article-title":"Across-the-board review on Omicron SARS-CoV-2 variant","volume":"33","author":"Wasim","year":"2025","journal-title":"Inflammopharmacology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jgg.2021.12.003","article-title":"Evidence for a mouse origin of the SARS-CoV-2 Omicron variant","volume":"48","author":"Wei","year":"2021","journal-title":"J. Genet. Genomics"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade4790","article-title":"An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults","volume":"15","author":"Widge","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.5001\/omj.2024.103","article-title":"COVID-19 pandemic and its impact on vaccine hesitancy: A review","volume":"39","author":"Widyaningsih","year":"2024","journal-title":"Oman Med. J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"17749","DOI":"10.1021\/acsnano.4c03075","article-title":"A nanoparticle vaccine displaying conserved epitopes of the preexisting neutralizing antibody confers broad protection against SARS-CoV-2 variants","volume":"18","author":"Wu","year":"2024","journal-title":"ACS Nano"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125597","article-title":"Self-Assembling protein nanoparticle platform for multivalent antigen delivery in vaccine development","volume":"676","author":"Wu","year":"2025","journal-title":"Int. J. Pharm."},{"key":"B46","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41541-021-00392-7","article-title":"A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge","volume":"6","author":"Wuertz","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B47","doi-asserted-by":"publisher","first-page":"7715","DOI":"10.1038\/s41467-024-51973-8","article-title":"Structural basis for the evolution and antibody evasion of SARS-CoV-2 BA.2.86 and JN.1 subvariants","volume":"15","author":"Yang","year":"2024","journal-title":"Nat. Commun."},{"key":"B48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41392-025-02139-5","article-title":"Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1392898","article-title":"Strategies for developing self-assembled nanoparticle vaccines against SARS-CoV-2 infection","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1676592\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T07:12:56Z","timestamp":1762240376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1676592\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":49,"alternative-id":["10.3389\/fcimb.2025.1676592"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1676592","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"article-number":"1676592"}}